Add to ORKGThe incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, an...
BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
Item does not contain fulltextThe incidence of endometrial carcinoma is rising and the patients with...
Abstract Background Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal c...
Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer i...
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that predominantly inhibits v...
can be determined for recommended treatment options. h th dia of the malignant cells, with some or a...
pazopanib in breast cancer. The content of this article has been reviewed by independent peer review...
Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available ther...
Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With rela...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, an...
BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
Item does not contain fulltextThe incidence of endometrial carcinoma is rising and the patients with...
Abstract Background Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal c...
Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer i...
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that predominantly inhibits v...
can be determined for recommended treatment options. h th dia of the malignant cells, with some or a...
pazopanib in breast cancer. The content of this article has been reviewed by independent peer review...
Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available ther...
Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With rela...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, an...
BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patie...